ISM5411 not checked
InSilico Medicine Hong Kong Limited
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Dosage Form: Tablet ; Frequency of administration: Orally QD.”In the company’s words, NCT07265570 on ClinicalTrials.gov
- Tested for
- Ulcerative Colitis
- Main trialPhase 2
- “This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of ISM5411 in adult patients with active ulcerative colitis.”In the company’s words, NCT07265570 on ClinicalTrials.gov
- Other names
- Garutadustat
Other drugs for Ulcerative Colitis
- TofacitinibPfizer · Phase 3
- UpadacitinibAbbVie · Phase 3
- RisankizumabAbbVie · Phase 3
- UstekinumabJanssen Research & Development, LLC · Phase 3
- IcotrokinraJanssen Research & Development, LLC · Phase 3
- ObefazimodAbivax S.A. · Phase 3
Coming up1
- 15 Aug 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 15 Aug 2027 | Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA) | |
| Phase 1Completed | 4 Sep 2024 | Study Evaluating ISM5411 Administered Orally to Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026